GE Healthcare
PRESS RELEASE
Bridgeway Diagnostics Installs SenoClaire, New Breast Imaging with 3D
Tomosynthesis Solution
December 1, 2014 — Bridgeway Diagnostics today becomes the first center in the Southeast
Region to install SenoClaire*, GE Healthcare’s (NYSE: GE) new breast tomosynthesis solution
designed with a three-dimensional imaging technology. SenoClaire, which was approved by
the FDA in September, uses a low-dose short X-ray sweep around the positioned breast with
nine exposures acquired with a “step-and-shoot” method, removing the potential motion
from the tube helping to reduce blur and increase image sharpness.
“We are pleased to be working with GE Healthcare to provide women with the most precise
screening tool available to help detect breast cancer,” said Dr. Jason Hoover, Bridgeway
Diagnostics Medical Director. “When cancer is identified and treated earlier, we know
women have a better rate of survival.””
Bridgeway Diagnostics is a new outpatient imaging center located in Phenix City, AL and
serves patients in both Alabama and Georgia, accepting most insurances in AL and GA.
Bridgeway was actually the first imaging center in the country to purchase SenoClaire.
“Like GE Healthcare, Bridgeway Diagnostics is committed to offering its physicians a
complete suite of solutions – from screening and diagnosis through treatment and
monitoring,” said Catherine Tabaka, Chief Marketing Officer, GE Healthcare, Detection and
Guidance Solutions. “SenoClaire will offer the network’s patients a new solution to help
clinicians better detect breast cancer with low dose radiation and high image quality.”
A key challenge when performing screening mammography is keeping the radiation levels as
low as possible. With GE’s SenoClaire, there is no increase in dose from a 2D standard
mammogram to a 3D view, which means there is no increased radiation to patients during a
SenoClaire breast exam.
“SenoClaire marks a significant step forward in helping our clinicians detect breast cancer.”
said Dr. Hoover. “At Bridgeway Diagnostics, we provide our patient with the most effective
ways to battle cancer from every possible angle, with innovative procedures, medicines and
technology.”
In addition to offering more clarity, confidence and low dose, SenoClaire offers a complete
solution by helping to improve overall workflow. SenoClaire is compatible with CentricityTM
PACS with Universal Viewer and supports the DICOM standard that can be read by capable
PACS vendors. When SenoClaire is combined with GE Healthcare’s Centricity PACS and
Centricity Clinical Archive solution², clinicians have access to the patient’s longitudinal
record, providing data that helps to enable better patient care.
GE Healthcare is actively working on SenoClaire installations throughout 2014 and into
2015. Currently, GE Healthcare has 180 units installed in Europe, Australia, Latin America,
Southeast Asia and the Middle East.
About GE Healthcare
GE Healthcare provides transformational medical technologies and services to meet the
demand for increased access, enhanced quality and more affordable healthcare around the
world. GE (NYSE: GE) works on things that matter - great people and technologies taking on
tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics
to drug discovery, biopharmaceutical manufacturing technologies and performance
improvement solutions, GE Healthcare helps medical professionals deliver great healthcare
to their patients.
Tackling Cancer
At GE, we envision a day when cancer is no longer a deadly disease. In September 2011, GE
Healthcare launched an ambitious global campaign against cancer, committing $1 billion of
its total R&D budget over the next five years to expand its advanced cancer diagnostic and
molecular imaging capabilities, as well as its advanced technologies for the manufacture of
biopharmaceuticals and for cancer research. By the end of 2012, $335M had been invested,
setting GE on track to meet its five-year commitment. To accelerate progress, and to help
clinicians deliver better care to 10 million patients by 2020, the campaign against cancer
combines the strength of GE’s portfolio of cancer technologies with the innovations born
from collaborations with key partners. To learn more on how GE is tackling cancer, see:
http://www.getacklingcancer.com/.
About Bridgeway Diagnostics
5007 Summerville Rd. Phenix City, AL 36867
888-588-5185 (toll free)
334-408-2854
www.2bridgeway.com
Services offered: MRI, Low Dose CT, Mammography/3D Low Radiation Dose Breast
Tomography, 3D Automated Breast Ultrasound, 3D/4D Ultrasound, X-ray, Fluoroscopy,
Dexa/Bone Density Scans, Body Composition Scans, Echocardiograms
Media Contacts
GE Healthcare
Jennifer Fox
Manager, PR & Global Communications, DGS
jennifer.r.fox@ge.com
+1 414-721-3813
Bridgeway Diagnostics
Tracy Shackett
Director of Marketing
tshackett@2bridgeway.com
706-676-1233
*Trademark of General Electric Company
©2014 General Electric Company – All rights reserved. Centricity, GE and GE Monogram are trademarks of General Electric Company. GE Healthcare, a
division of General Electric Company.